Johnson & Johnson has filled in some of the details of its $55 billion investment in US facilities announced earlier this ...

Telehealth company Ro has a new spokesperson for its booming GLP-1 business: Serena Williams, the 23-time Grand Slam champion ...

The positive data from the Phase 3 Denali trial showed that NCX 470, a nitric oxide-donating bimatoprost eyedrop formulation, ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he will withdraw from negotiations ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

This month’s executive moves in the agency, consultancy, and investor sectors reflect a growing emphasis on strategic ...

Among the plans will be greater first-line use of SGLT-2 inhibitors or 'gliflozin' drugs, which are mainly used second-line ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

Twin Health has raised another $53 million to fund its 'digital twin' platform, which provides a model of a patient's unique ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...